Evidence map›Paper›PMID 27115672›Full record

ArticleJournal of molecular neuroscience : MN2016

SEPT14 Is Associated with a Reduced Risk for Parkinson's Disease and Expressed in Human Brain.

Liron Rozenkrantz, Ziv Gan-Or, Mali Gana-Weisz, Anat Mirelman, Nir Giladi, Anat Bar-Shira, Avi Orr-Urtreger

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Effects ofFrontiers in molecular neuroscience · 2022
    Article
  5. Article
  6. Article
  7. Journal of clinical medicine · 2019
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Liron RozenkrantzThe Genetic Institute, Tel-Aviv Sourasky Medical Center, Weizmann 10, 64239, Tel Aviv, Israel.
Ziv Gan-OrThe Genetic Institute, Tel-Aviv Sourasky Medical Center, Weizmann 10, 64239, Tel Aviv, Israel.
Mali Gana-WeiszThe Genetic Institute, Tel-Aviv Sourasky Medical Center, Weizmann 10, 64239, Tel Aviv, Israel.
Anat MirelmanMovement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center, Weizmann 10, 64239, Tel-Aviv, Israel.
Nir GiladiSackler Faculty of Medicine, Tel-Aviv University, 39040, Tel-Aviv, Israel.
Anat Bar-ShiraThe Genetic Institute, Tel-Aviv Sourasky Medical Center, Weizmann 10, 64239, Tel Aviv, Israel.
Avi Orr-UrtregerThe Genetic Institute, Tel-Aviv Sourasky Medical Center, Weizmann 10, 64239, Tel Aviv, Israel. aviorr@tasmc.health.gov.il.
Tel Aviv Sourasky Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genes involved in cytoskeletal stability and trafficking, such as MAPT and SNCA, are important risk factors for Parkinson's disease (PD). Two members of the cytoskeletal Septin family, SEPT4 and SEPT5, were implicated in PD pathobiology. We aimed to determine whether Septin genes are associated with Parkinson's disease. To this end, six SNPs located in four different Septin loci were analyzed in 720 PD patients and 740 controls, all of Ashkenazi-Jewish origin. In addition, SEPT14 was sequenced and its expression was determined in different human tissues. Our results revealed that two SNPs in the SEPT14 locus, rs11981883 and rs10241628, were associated with a reduced risk for PD (p = 0.02 and p = 0.005). A third SNP, rs77231105, was localized in the putative promoter of SEPT14 and was predicted to affect the binding of the transcription factor Nkx2.5. This SNP was also associated with a reduced risk for PD (OR = 0.28, p < 0.0007). The three SEPT14 SNPs defined a protective haplotype which significantly reduced the risk for PD by 4-fold (p = 0.002). SEPT14 was found to be expressed in the brain and in the Substantia Nigra. These results suggest that SEPT14 may have a protective role in Parkinson's disease pathogenesis, yet more studies are necessary to validate these results.

Indexed as

Polymorphism, Single NucleotideAgedBrainCase-Control StudiesFemaleHaplotypesHumansMaleMiddle AgedParkinson DiseaseSeptinsSEPTIN14 protein, humanSeptinsGeneticsParkinson’s diseaseSEPT14Septin 14

Identifiers

PMID27115672
OpenAlexW2344354737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.